Horus® Fiber Optic Laser DCR by Invamed is specifically designed for minimally invasive tear duct surgery (dacryocystorhinostomy) using endoscopic laser technology. This system integrates high-performance fiber optics with precise laser control, enabling surgeons to create a new tear drainage pathway while minimizing trauma to surrounding nasal and lacrimal structures. The result is enhanced visualization, swift recovery, and long-term lacrimal system patency for patients suffering from nasolacrimal duct obstruction.
Targeted Laser Fiber Optic Delivery
- The fiber optic cable is engineered to channel laser energy directly to the lacrimal sac and nasal cavity junction, ensuring a clean and focused ablation path.
- Minimizes collateral tissue damage around delicate nasal mucosa and lacrimal sac structures.
High-Precision Laser Output
- Utilizes a medical-grade laser (diode or holmium, based on product code) for consistent power delivery.
- Offers variable laser energy settings, allowing surgeons to adjust ablation intensity to address different tissue thicknesses or scarring.
Biocompatible Fiber Construction
- Horus® fiber is fabricated from medical-grade fused silica and covered with a durable polymer sheath resistant to repeated sterilization.
- Maintains optimal light and laser transmission throughout the procedure, preserving brightness and laser focus.
Easy Integration with Endoscopic Systems
- Universal fiber connectors adapt to standard endoscopic lasers or integrated ENT/ophthalmic workstations, streamlining OR setups.
- Compatible with endoscopic camera systems, facilitating simultaneous visualization of the operative field and precise laser fiber placement.
Minimally Invasive DCR Approach
- Reduces external scarring compared to external DCR techniques, enabling faster healing and improved cosmetic outcomes.
- Well-suited for patients with nasolacrimal duct obstructions requiring direct endonasal access and laser-based tissue ablation.
Clinical Indications
- Primary or revision endoscopic dacryocystorhinostomy in patients with chronic tear duct obstruction, failed nasolacrimal stent treatments, or recurrent dacryocystitis.
- Especially beneficial for scarred anatomies or when alternative approaches have proven challenging.